Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carboplatin + Pemetrexed Disodium + VT3989 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| Pemetrexed Disodium | Alimta | LY231514|Ciambra|pemetrexed | Chemotherapy - Antimetabolite 14 | Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary). |
| VT3989 | VT-3989|VT 3989 | VT3989 inhibits the auto-palymitoylation of TEAD, which leads to impaired YAP function, potentially leading to inhibition of tumor growth (Cancer Res (2023) 83 (8_Supplement): CT006). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04665206 | Phase Ib/II | Carboplatin + Pemetrexed Disodium + VT3989 Ipilimumab + Nivolumab + VT3989 Osimertinib + VT3989 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |